1. Acknowledgement to Referees

   Acknowledgement to Referees 17 November 2020 Pages: 693 - 696

2. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy

   • Nicholas Theodoropoulos
   • Guido Lancman
   • Ajai Chari

   Review Article 19 October 2020 Pages: 697 - 708

   

3. Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data

   • Dawid Sigorski
   • Ewa Iżycka-Świeszewska
   • Lubomir Bodnar

   Review Article Open access 12 October 2020 Pages: 709 - 722

4. Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis

   • Jacques Raphael
   • Cory Lefebvre
   • Phillip S Blanchette

   Systematic Review 05 November 2020 Pages: 723 - 732

   

5. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

   • Julie G. Fisher
   • David Tait
   • Richard L. Schilsky

   Original Research Article 22 October 2020 Pages: 733 - 741

   

6. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

   • Tareq Al Baghdadi
   • Elizabeth Garrett-Mayer
   • Richard L. Schilsky

   Original Research Article 17 October 2020 Pages: 743 - 750

   

7. Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry

   • Li Chia Chong
   • Jennifer E. Hardingham
   • Timothy J. Price

   Original Research Article 17 October 2020 Pages: 751 - 757

   

8. A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping

   • Baptiste Louveau
   • Fanélie Jouenne
   • Samia Mourah

   Original Research Article 05 November 2020 Pages: 759 - 771

   

9. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

   • Giulia Orsi
   • Francesco Tovoli
   • Andrea Casadei-Gardini

   Original Research Article 12 October 2020 Pages: 773 - 785

   

10. SB8: A Bevacizumab Biosimilar

    • Yahiya Y. Syed

    Adis Biosimilar Brief Open access 18 November 2020 Pages: 787 - 790

    

11. Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer

    • Lesley J. Scott

    Adis Drug Evaluation Open access 25 November 2020 Pages: 791 - 799

    

12. Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study

    • Luca Faloppi
    • Marco Puzzoni
    • Mario Scartozzi

    Correction 10 November 2020 Pages: 801 - 802

13. Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

    • Ramesh K. Ramanathan
    • Daniel D. Von Hoff
    • Klaus Mross

    Correction Open access 27 October 2020 Pages: 803 - 803

14. Correction to: Biologic Drug Quality Assurance to Optimize HER2+ Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3

    • Diana Lüftner
    • Gary H. Lyman
    • Minji Seo

    Correction 20 October 2020 Pages: 805 - 805

15. Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product

    • Dietger Niederwieser
    • Caroline Hamm
    • David Chien

    Correction Open access 12 November 2020 Pages: 807 - 807

16. Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

    • Giulia Orsi
    • Francesco Tovoli
    • Andrea Casadei-Gardini

    Correction 28 October 2020 Pages: 809 - 810